Zheng, Elizabeth X.
Rossi, Simona
Fontana, Robert J.
Vuppalanchi, Raj
Hoofnagle, Jay H.
Khan, Ikhlas
Navarro, Victor J.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases
Article History
First Online: 17 May 2016
Compliance with Ethical Standards
:
: Elizabeth Zheng, Simona Rossi, Robert Fontana, Raj Vuppalanchi, Jay Hoofnagle, Iklhas Khan and Victor Navarro have no conflicts of interest that are directly relevant to the content of this study.
: The Drug-Induced Liver Injury Network (DILIN) is structured as a U01 cooperative agreement supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH) with funds provided by the following Grants: U01DK065211 (Indiana University [Purdue]), U01DK065184 (University of Michigan [Ann Arbor]), U01DK065201 (University of North Carolina [Chapel Hill], Asheville, Wake Forest Baptist Medical Center), U01DK083020 (University of Southern California, University of California–Los Angeles [Pfleger Liver Institute]), U01DK083027 (Albert Einstein Medical Center), U01DK100928 (Icahn School of Medicine at Mount Sinai), U01DK065176 (Duke Clinical Research Institute). Additional support was provided by the Intramural Division of the National Cancer Institute (NCI), NIH.